Tradestie Institutional Equity Comparison Engine

XMAX vs ADIL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ADIL Overall Edge

ADIL Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Adial Pharmaceuticals, Inc (ADIL) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, XMAX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ADIL at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XMAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ADIL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
XMAX N/M vs ADIL N/M Fwd P/E
Growth & Margin Winner ADIL
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner ADIL
1Y -23.9% vs +1283.9% ยท 52W Pos 47% vs 70%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XMAX US Equity
XMAX
Institutional Equity
$6.01
+0.33% 1D
Market Cap N/A
1M Return -31.31%
1Y Return -23.92%
Forward P/E N/M
Unified AI Score
46.4 / 100 HOLD
Tech 45.0 Fund 49.0 Flow 50.0 Mom 54.0
ADIL NASDAQ
Adial Pharmaceuticals, Inc
Pharmaceutical Preparations
$5.05
+36.12% 1D
Market Cap $9.7M
1M Return +21.69%
1Y Return +1283.94%
Forward P/E N/M
Unified AI Score
32.8 / 100 SELL
Tech 5.0 Fund 36.0 Flow 50.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XMAX -23.92% ADIL +1283.94% Spread: +210.24 pp (ADIL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XMAX TTM Op. Margin: N/A ADIL TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XMAX vs ADIL. Trailing 12-month operating profitability (XMAX N/A vs ADIL 0.0%) and valuation multiples (XMAX N/M vs ADIL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XMAX (1) vs ADIL (7)
Institutional Metric XMAX ADIL Criterion Row Winner
Market Capitalization Scale N/A $9.7M Larger Scale ADIL
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth ADIL
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin ADIL
Net Profit Margin Profitability N/A 0.0% Higher Margin ADIL
Return on Equity (ROE) Capital Efficiency N/A -2011.6% Higher ROE ADIL
52-Week Range Position Momentum 47% ($3โ€“$9) 70% ($0โ€“$7) Stronger Trend ADIL
Beta / 30D Volatility Risk Regime 1.90ฮฒ ยท 195% Vol 0.63ฮฒ ยท 153% Vol Lower Realized Risk ADIL
Unified Institutional Score Composite Signal 46.4 / 100 (HOLD) 32.8 / 100 (SELL) Higher Composite XMAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XMAX vs ADIL Buy Guide
XMAX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live XMAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ADIL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ADIL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XMAX nor ADIL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.